SSI Strategy Acquired by Clinigen — Healthcare M&A

Clinigen has completed the acquisition of SSI Strategy, a healthcare services other business in the United States, for $25 million. Clinigen acquisitions expand pharma services capabilities, combining drug development consultancy support with commercialization and administrative and regulatory services. SSI Strategy provides drug development consulting that supports clinical trials, regulatory readiness, and commercialization planning for pharmaceutical clients. The add on acquisition is part of Clinigen’s private equity acquisition strategy as a platform company of Triton Partners, with the deal announced and size reported at $25 million.